Michael Löw

Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

Meletios Α. Dimopoulos, Vânia Hungria, Atanas Radinoff et al. · The Lancet Haematology · 2023 · 113 citations

Hematological Malignancy, Oncology, Metronomic Therapy +10

Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre

Thanh T. Nguyen, Trevor Gin, Kathy Nicholls et al. · Clinical and Experimental Ophthalmology · 2005 · 100 citations

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos

Pasquale L. Fedele, Simon N. Willis, Yang Liao et al. · Blood · 2018 · 87 citations · Full text

Hemodynamics in rigid and distensible saccular aneurysms: A numerical study of pulsatile flow characteristics

Michael Löw, Karl Perktold, R. Raunig · Biorheology · 1993 · 80 citations

Engineering, Fluid Mechanics, Lateral Model Aneurysms +18

IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis

Michael Löw, Erica J. Brodie, Pasquale L. Fedele et al. · Cell Reports · 2019 · 75 citations · Full text